v3.25.1
Other Noncurrent Liabilities
 3 Months Ended
Mar. 31, 2025
Other Liabilities, Noncurrent [Abstract]  
Other Liabilities Noncurrent Other Noncurrent Liabilities:
Other noncurrent liabilities consist of the following at March 31, 2025 and December 31, 2024 (in thousands):
March 31,December 31,
20252024
Transition tax on foreign earnings(a)
$44,647 $44,647 
Operating leases(b)
101,349 99,514 
Liabilities related to uncertain tax positions242,611 259,586 
Executive deferred compensation plan obligation34,552 38,243 
Environmental liabilities(c)
15,926 15,783 
Asset retirement obligations96,724 94,854 
Tax indemnification liability(d)
11,044 12,567 
Deferred revenue406,152 78,027 
Capital expenditure incentive payables(e)
74,506 74,506 
Other(f)
98,432 101,477 
Total$1,125,943 $819,204 
(a)Noncurrent portion of one-time transition tax on foreign earnings.
(b)See Note 13, “Leases.”
(c)See Note 7, “Commitments and Contingencies.”
(d)Indemnification of certain income and non-income tax liabilities, primarily associated with the Chemetall Surface Treatment entities sold in 2017.
(e)When constructing new facilities or making major enhancements to existing facilities, we may have the opportunity to enter into incentive agreements with local government agencies in order to reduce certain state and local tax expenditures. Under these agreements, we transfer the related assets to various local government entities and receive bonds. We immediately lease the facilities from the local government entities and have an option to repurchase the facilities for a nominal amount upon tendering the bonds to the local government entities at various predetermined dates. The bonds and the associated obligations for the leases of the facilities offset values, and the underlying assets are recorded in property, plant and equipment.
(f)No individual component exceeds 5% of total liabilities.
In the normal course of business, amounts received from customers in advance of the Company’s satisfaction of its contractual performance obligations are recorded as deferred revenue, and are recognized within Net sales as the Company satisfies the related performance obligation. During the three-month period ended March 31, 2025, the Company received $350 million from a customer for the delivery of specified amounts of spodumene and lithium salts over the next 5 years. $21.9 million of deferred revenue is expected to be recognized within Net sales over the next twelve months and is reported in Accrued expenses on the consolidated balance sheet. There was no deferred revenue recognized in Net sales during the three-month period ended March 31, 2025.